A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant.

Trial Profile

A Phase I/II, Observer-Blind, Randomized, Active-Controlled Trial to Evaluate the Safety and Immunogenicity of a Two-Dose Series of GSK Biologicals' Candidate Influenza Vaccine GSK 1557484A Antigens With or Without Adjuvant.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; AS03A; AS03B
  • Indications Influenza A virus H5N1 subtype; Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Apr 2010 Results reported in the Journal of Infectious Diseases.
    • 10 Mar 2008 The expected completion date for this trial is now 1 Feb 2008.
    • 05 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top